Clinical Trial Update: Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

This update reports results from a Phase 2 study evaluating weekly bortezomib (Velcade) in patients with refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED